Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANeED study of ambroxol in prodromal and mild dementia with Lewy bodies
2024-510720-38-00Phase 2Authorised
- Sponsor
- Helse Fonna
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dementia with Lewy bodies (DLB) and mild cognitive impairment with Lewy bodies (MCI-LB) comparing Ambroxol with Placebo (2 arms). Primary endpoint: MMSE change from screening to 18 months. Planned start Jan 2021; status: authorised.
02
Drugs
ambroxol
03
Conditions
dementia with Lewy bodies (DLB)mild cognitive impairment with Lewy bodies (MCI-LB)
Beyond the preview
Go deeper on 2024-510720-38-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510720-38-00.